GSK Moves to Dismiss Plaintiffs' Claims that Fall Outside LPLA

NEW ORLEANS - The manufacturer of Avandia moved to dismiss a majority of the claims asserted by ten plaintiffs who allegedly sustained injuries as a result of using the diabetes drug because the allegations fall outside the scope of the Louisiana Products Liability Act (LPLA). Linda Edwards, et al., v. GlaxoSmithKline, Inc., No. 03-1198 (E.D. La.).

GlaxoSmithKline's (GSK) Oct. 17 motion to dismiss contended that four of the five causes of actions alleged in the plaintiffs' complaint consisted of theories of recovery outside the permissible scope of the LPLA.

Under the LPLA, plaintiffs seeking to recover damages for injuries caused …